Keywords: ADSS1 myopathy; Adenylosuccinate synthetase 1 myopathy; Biomarkers; Cardiac muscle; Clinical presentation; Consortium; Guidelines; Inborn error of metabolism; Pre-clinical models; Purine disorder; Skeletal muscle; Therapeutics; Ultra-rare neuromuscular disease.